A Broad-Spectrum Antiviral Molecule, Protoporphyrin IX, Acts as a Moderator of HIV-1 Capsid Assembly by Targeting the Capsid Hexamer

CA and its assembled viral core play essential roles in distinct steps during HIV-1 replication, including reverse transcription, integration, nuclear entry, virus assembly, and maturation through CA–CA or CA–host factor interactions. These functions of CA are fundamental for HIV-1 pathogenesis, making it an appealing target for antiviral therapy. ABSTRACT The capsid protein (CA), an essential component of human immunodeficiency virus type 1 (HIV-1), represents an appealing target for antivirals. Small molecules targeting the CAI-binding cavity in the C-terminal domain of HIV-1 CA (CA CTD) confer potent antiviral activities. In this study, we report that a small molecule, protoporphyrin IX (PPIX), targets the HIV-1 CA by binding to this pocket. PPIX was identified via in vitro drug screening, using a homogeneous and time-resolved fluorescence-based assay. CA multimerization and a biolayer interferometry (BLI) assay showed that PPIX promoted CA multimerization and bound directly to CA. The binding model of PPIX to CA CTD revealed that PPIX forms hydrogen bonds with the L211and E212 residues in the CA CTD. Moreover, the BLI assay demonstrated that this compound preferentially binds to the CA hexamer versus the monomer. The superposition of the CAI CTD-PPIX complex and the hexameric CA structure suggests that PPIX binds to the interface formed by the NTD and the CTD between adjacent protomers in the CA hexamer via the T72 and E212 residues, serving as a glue to enhance the multimerization of CA. Taken together, our studies demonstrate that PPIX, a hexamer-targeted CA assembly enhancer, should be a new chemical probe for the discovery of modulators of the HIV-1 capsid assembly. IMPORTANCE CA and its assembled viral core play essential roles in distinct steps during HIV-1 replication, including reverse transcription, integration, nuclear entry, virus assembly, and maturation through CA–CA or CA–host factor interactions. These functions of CA are fundamental for HIV-1 pathogenesis, making it an appealing target for antiviral therapy. In the present study, we identified protoporphyrin IX (PPIX) as a candidate CA modulator that can promote CA assembly and prefers binding the CA hexamer versus the monomer. PPIX, like a glue, bound at the interfaces between CA subunits to accelerate CA multimerization. Therefore, PPIX could be used as a new lead for a CA modulator, and it holds potential research applications.

[1]  William M. McFadden,et al.  Rotten to the core: antivirals targeting the HIV-1 capsid core , 2021, Retrovirology.

[2]  E. De Clercq,et al.  Design, synthesis, and mechanism study of dimerized phenylalanine derivatives as novel HIV-1 capsid inhibitors. , 2021, European journal of medicinal chemistry.

[3]  M. Matsuoka,et al.  A Small Molecule, ACAi-028, with Anti-HIV-1 Activity Targets a Novel Hydrophobic Pocket on HIV-1 Capsid , 2021, bioRxiv.

[4]  H. Tamamura,et al.  Small-Molecule Anti-HIV-1 Agents Based on HIV-1 Capsid Proteins , 2021, Biomolecules.

[5]  D. Qu,et al.  Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2 , 2020, Science Bulletin.

[6]  A. Fauci,et al.  Four Decades of HIV/AIDS - Much Accomplished, Much to Do. , 2020, The New England journal of medicine.

[7]  J. R. Somoza,et al.  Clinical targeting of HIV capsid protein with a long-acting small molecule , 2020, Nature.

[8]  Jian He,et al.  Broad-spectrum antivirals of protoporphyrins inhibit the entry of highly pathogenic emerging viruses , 2020, bioRxiv.

[9]  Lei Xu,et al.  Natural product library-based screening for discovery of capsid C-terminal domain targeted HIV-1 inhibitors. , 2020, International journal of antimicrobial agents.

[10]  P. Zhan,et al.  Design, synthesis and structure-activity relationships of 4-phenyl-1H-1,2,3-triazole phenylalanine derivatives as novel HIV-1 capsid inhibitors with promising antiviral activities. , 2020, European journal of medicinal chemistry.

[11]  T. Ndung’u,et al.  Why and where an HIV cure is needed and how it might be achieved , 2019, Nature.

[12]  A. Brass,et al.  A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model , 2019, Nature Medicine.

[13]  A. Engelman,et al.  A HTRF based competitive binding assay for screening specific inhibitors of HIV-1 capsid assembly targeting the C-Terminal domain of capsid. , 2019, Antiviral research.

[14]  E. Freed,et al.  Multiple Roles of HIV-1 Capsid during the Virus Replication Cycle , 2019, Virologica Sinica.

[15]  C. Aiken,et al.  PF74 Reinforces the HIV-1 Capsid To Impair Reverse Transcription-Induced Uncoating , 2018, Journal of Virology.

[16]  C. Aiken,et al.  Inhibitors of the HIV-1 capsid, a target of opportunity , 2018, Current opinion in HIV and AIDS.

[17]  M. Parker,et al.  Kinetics of HIV-1 capsid uncoating revealed by single-molecule analysis , 2018, eLife.

[18]  Jimmy P. Xu,et al.  Exploring Modifications of an HIV-1 Capsid Inhibitor: Design, Synthesis, and Mechanism of Action. , 2018, Journal of drug design and research.

[19]  A. M. Gomes,et al.  Mechanisms of Vesicular Stomatitis Virus Inactivation by Protoporphyrin IX, Zinc-Protoporphyrin IX, and Mesoporphyrin IX , 2017, Antimicrobial Agents and Chemotherapy.

[20]  S. Geschwindner,et al.  Harnessing the Versatility of Optical Biosensors for Target-Based Small-Molecule Drug Discovery. , 2017, ACS sensors.

[21]  Greg J. Towers,et al.  HIV-1 uses dynamic capsid pores to import nucleotides and fuel encapsidated DNA synthesis , 2016, Nature.

[22]  Suzie Thenin-Houssier,et al.  HIV-1 Capsid Inhibitors as Antiretroviral Agents. , 2016, Current HIV research.

[23]  Jimmy P. Xu,et al.  Identification of a small molecule HIV-1 inhibitor that targets the capsid hexamer. , 2016, Bioorganic & medicinal chemistry letters.

[24]  K. Anderson,et al.  Protoporphyrin IX: the Good, the Bad, and the Ugly , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[25]  Ian Mitchelle S. de Vera,et al.  Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication , 2016, Antimicrobial Agents and Chemotherapy.

[26]  Joe D. Lewis,et al.  Specific Inhibitors of HIV Capsid Assembly Binding to the C-Terminal Domain of the Capsid Protein: Evaluation of 2-Arylquinazolines as Potential Antiviral Compounds. , 2016, Journal of medicinal chemistry.

[27]  T. Hope,et al.  HIV-1 capsid: the multifaceted key player in HIV-1 infection , 2015, Nature Reviews Microbiology.

[28]  E. Freed,et al.  HIV-1 assembly, release and maturation , 2015, Nature Reviews Microbiology.

[29]  J. R. Somoza,et al.  Functional label-free assays for characterizing the in vitro mechanism of action of small molecule modulators of capsid assembly. , 2015, Biochemistry.

[30]  Jeffrey E. Lee,et al.  Measuring Protein‐Protein and Protein‐Nucleic Acid Interactions by Biolayer Interferometry , 2015, Current protocols in protein science.

[31]  A. Debnath,et al.  Dual-acting stapled peptides target both HIV-1 entry and assembly , 2013, Retrovirology.

[32]  A. Debnath,et al.  Dual-acting stapled peptides target both HIV-1 entry and assembly , 2013, Retrovirology.

[33]  Jean-François Mercier,et al.  Discovery of Novel Small-Molecule HIV-1 Replication Inhibitors That Stabilize Capsid Complexes , 2013, Antimicrobial Agents and Chemotherapy.

[34]  J. Mercier,et al.  Novel inhibitor binding site discovery on HIV-1 capsid N-terminal domain by NMR and X-ray crystallography. , 2013, ACS chemical biology.

[35]  Xiaohong Liu,et al.  Large-Scale Functional Purification of Recombinant HIV-1 Capsid , 2013, PloS one.

[36]  Wim F Vranken,et al.  ACPYPE - AnteChamber PYthon Parser interfacE , 2012, BMC Research Notes.

[37]  R. Ptak,et al.  Inhibiting Early-Stage Events in HIV-1 Replication by Small-Molecule Targeting of the HIV-1 Capsid , 2012, Journal of Virology.

[38]  Wesley I. Sundquist,et al.  Distinct Effects of Two HIV-1 Capsid Assembly Inhibitor Families That Bind the Same Site within the N-Terminal Domain of the Viral CA Protein , 2012, Journal of Virology.

[39]  Aurélien Grosdidier,et al.  Fast docking using the CHARMM force field with EADock DSS , 2011, J. Comput. Chem..

[40]  Y. Takebe,et al.  Novel Postentry Inhibitor of Human Immunodeficiency Virus Type 1 Replication Screened by Yeast Membrane-Associated Two-Hybrid System , 2011, Antimicrobial Agents and Chemotherapy.

[41]  Aurélien Grosdidier,et al.  SwissDock, a protein-small molecule docking web service based on EADock DSS , 2011, Nucleic Acids Res..

[42]  Katsushi Inoue,et al.  Novel development of 5-aminolevurinic acid (ALA) in cancer diagnoses and therapy. , 2011, International immunopharmacology.

[43]  A. Debnath,et al.  Antiviral activity of α-helical stapled peptides designed from the HIV-1 capsid dimerization domain , 2011, Retrovirology.

[44]  J. Nieman,et al.  HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention , 2010, PLoS pathogens.

[45]  Johannes Ottl,et al.  Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads , 2010, Expert opinion on drug discovery.

[46]  Richard G. Jenner,et al.  Gyrase B Inhibitor Impairs HIV-1 Replication by Targeting Hsp90 and the Capsid Protein* , 2010, The Journal of Biological Chemistry.

[47]  Mark Yeager,et al.  Disulfide bond stabilization of the hexameric capsomer of human immunodeficiency virus. , 2010, Journal of molecular biology.

[48]  T. Hawkins.  Understanding and managing the adverse effects of antiretroviral therapy. , 2010, Antiviral research.

[49]  Joe Lewis,et al.  Residues in the HIV-1 Capsid Assembly Inhibitor Binding Site Are Essential for Maintaining the Assembly-competent Quaternary Structure of the Capsid Protein* , 2008, Journal of Biological Chemistry.

[50]  A. Debnath,et al.  A cell-penetrating helical peptide as a potential HIV-1 inhibitor. , 2008, Journal of molecular biology.

[51]  Gerrit Groenhof,et al.  GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..

[52]  Hans-Georg Kräusslich,et al.  The HIV-1 capsid protein C-terminal domain in complex with a virus assembly inhibitor , 2005, Nature Structural &Molecular Biology.

[53]  Barbara Müller,et al.  A peptide inhibitor of HIV-1 assembly in vitro , 2005, Nature Structural &Molecular Biology.

[54]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[55]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[56]  Wesley I. Sundquist,et al.  Assembly Properties of the Human Immunodeficiency Virus Type 1 CA Protein , 2004, Journal of Virology.

[57]  Wesley I. Sundquist,et al.  Functional Surfaces of the Human Immunodeficiency Virus Type 1 Capsid Protein , 2003, Journal of Virology.

[58]  Eric Barklis,et al.  Antiviral inhibition of the HIV-1 capsid protein. , 2003, Journal of molecular biology.

[59]  J. Briggs,et al.  Structural organization of authentic, mature HIV‐1 virions and cores , 2003, The EMBO journal.

[60]  P. Prevelige,et al.  Kinetic Analysis of the Role of Intersubunit Interactions in Human Immunodeficiency Virus Type 1 Capsid Protein Assembly In Vitro , 2002, Journal of Virology.

[61]  Wesley I. Sundquist,et al.  Image reconstructions of helical assemblies of the HIV-1 CA protein , 2022 .

[62]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[63]  W. Sundquist,et al.  Assembly and analysis of conical models for the HIV-1 core. , 1999, Science.

[64]  N. Oleinick,et al.  The photobiology of photodynamic therapy: cellular targets and mechanisms. , 1998, Radiation research.

[65]  Carol Carter,et al.  Crystal structure of dimeric HIV-1 capsid protein , 1996, Nature Structural Biology.

[66]  A. Debnath,et al.  Three-dimensional structure-activity analysis of a series of porphyrin derivatives with anti-HIV-1 activity targeted to the V3 loop of the gp120 envelope glycoprotein of the human immunodeficiency virus type 1. , 1994, Journal of medicinal chemistry.

[67]  H. Pass,et al.  Photodynamic therapy in oncology: mechanisms and clinical use. , 1993, Journal of the National Cancer Institute.

[68]  Shibo Jiang,et al.  Rapid Prescreening for Antiviral Agents against HIV-1 Based on Their Inhibitory Activity in Site-Directed Immunoassays. II. Porphyrins Reacting with the V3 Loop of gp120 , 1992 .